

**AOC Health GmbH
Frankfurt am Main**

**Announcement pursuant to Section 39 in conjunction with Section 23 (3) Sentence 1 No 1 of
the German Securities Acquisition and Takeover Act (*Wertpapiererwerbs- und
Übernahmegesetz*, "WpÜG")**

On June 29, 2020, AOC Health GmbH, Frankfurt am Main, ("**Bidder**") published the offer document ("**Offer Document**") for its mandatory offer to the shareholders of Vita 34 AG, Leipzig ("**Vita 34**") regarding the acquisition of all no-par value registered shares (ISIN DE000A0BL849) of Vita 34, including all ancillary rights at the time of settlement of the mandatory offer (in particular any entitlement to dividends) ("**Vita 34 Shares**"), in exchange for a cash payment of EUR 10.76 per share ("**Mandatory Offer**"). Excluded from this Mandatory Offer are all Vita 34 Shares already in possession of the Bidder, held by Vita 34 itself or held by a Vita 34 dependent or majority-owned company.

The acceptance period for the Mandatory Offer ends on July 27, 2020, 24:00 hours (CEST) unless extended pursuant to the legal provisions of the WpÜG.

1. As of July 3, 2020, 18:00 hours (CEST) ("**Reporting Date**") the Mandatory Offer has been accepted for 2,851 Vita 34 Shares. This corresponds to a rounded amount of 0.07% of the registered capital and the voting rights of Vita 34.
2. As of the Reporting Date, the Bidder held directly 1,132,464 Vita 34 Shares (this corresponds to a rounded amount of 27.31% of the registered capital and the voting rights of Vita 34). The voting rights associated with these Vita 34 Shares are attributed to the Further Controlling Parties (as defined in Section 4.3 of the Offer Document) pursuant to Section 30 (1) Sentence 1 No 1 Sentence 3 WpÜG.

As of the Reporting Date, Polski Bank Komórek Macierzystych S.A. (Warsaw, Poland) held directly 160,536 Vita 34 Shares (this corresponds to a rounded amount of 3.87% of the registered capital and the voting rights of Vita 34). The voting rights associated with these Vita 34 Shares are attributed to the Further Controlling Parties pursuant to Section 30 (1) Sentence 1 No 1 Sentence 3 WpÜG.

Consequently, the Bidder held directly 1,132,464 Vita 34 Shares, indirectly 160,536 Vita 34 Shares and in total 1,293,000 Vita 34 Shares (this corresponds to a rounded amount of 31.19% of the registered capital and the voting rights of Vita 34) as of the Reporting Date. The voting rights associated with these Vita 34 Shares are attributed to the Further Controlling Parties pursuant to Section 30 (1) Sentence 1 No 1 Sentence 3 WpÜG.

3. As of the Reporting Date, the Further Controlling Party Active Ownership Fund SICAV-FIS SCS (Grevenmacher, Grand Duchy of Luxembourg) held directly 100 Vita 34 Shares. This corresponds to a rounded amount of 0.002% of the registered capital and the voting rights of Vita 34. The voting rights associated with these Vita 34 Shares are attributed to the following Further Controlling Parties pursuant to Section 30 (1) Sentence 1 No 1 Sentence 3 WpÜG: Active Ownership Capital S.à r.l. (Grevenmacher, Grand Duchy of Luxembourg), Active Ownership Advisors GmbH (Frankfurt am Main), Florian Schuhbauer (Frankfurt am Main), Active Ownership Investments Limited (Limassol, Cyprus), Tamlino Import & Advisory LP (Limassol, Cyprus), Tamlino Investments Limited (Limassol, Cyprus) and Klaus Röhrig (Vienna, Austria).
4. Due to the Irrevocable Undertaking Gerth (as defined in Section 6.4(d) of the Offer Document), the Bidder directly held instruments pursuant to Section 38 (1) Sentence 1

No 2 German Securities Trading Act (*Wertpapierhandelsgesetz*, "**WpHG**") as of the Reporting Date, which enable their holder to acquire a total of 209,921 Vita 34 Shares, which have already been issued and contain voting rights (this corresponds to a rounded amount of 5.06% of the registered capital and voting rights of Vita 34). The instruments held by the Bidder are indirectly held by the Further Controlling Parties pursuant to Section 38 (1) Sentence 1 No 2 WpHG.

5. As of the Reporting Date, Vita 34 holds 47,806 of its own shares (this corresponds to a rounded amount of 1.15% of the registered capital and the voting rights of Vita 34). As described in Section 6.2 of the Offer Document, due to the attendance record at annual general meetings, the Bidder and its subsidiaries can assert a dominating influence on Vita 34 pursuant to Section 2 (6) 2nd. Alt. WpÜG. In accordance with the administrative practice of the German Federal Financial Supervisory Authority (*BaFin*), the voting rights associated with such Vita 34 Shares are not attributed to the Bidder or the Further Controlling Parties pursuant to Section 30 (1) Sentence 1 No. 1 WpÜG.
6. The total number of Vita 34 Shares for which the Mandatory Offer has been accepted as of the Reporting Date (for further details see Section 1 above), plus the Vita 34 Shares held directly and indirectly by the Bidder (for further details see Section 2 above), plus instruments related to the acquisition of Vita 34 Shares pursuant to Section 38 (1) Sentence 1 No 2 WpHG (for further details see Section 4 above), plus the Vita 34 Shares held directly by the Further Controlling Party Active Ownership Fund SICAV-FIS SCS (for further details see Section 3 above), amount to 1,505,872 Vita 34 Shares as of the Reporting Date. This corresponds to a rounded amount of 36.32% of the registered capital and voting rights of Vita 34.
7. Furthermore, as of the Reporting Date, neither the Bidder, nor parties acting in concert with the Bidder within the meaning of Section 2 (5) WpÜG or their subsidiaries within the meaning of Section 2 (6) WpÜG held any additional Vita 34 Shares or directly or indirectly held any shares of voting rights publishable pursuant to Sections 38 and 39 WpÜG or any additional voting rights attributable to them pursuant to Section 30 WpÜG.

Frankfurt a.M., July 6, 2020

AOC Health GmbH